SCHEMBL16632531

SCHEMBL16632531

COc1ccccc1Oc1cc(Cl)cc2oc(C#N)cc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A3 Q01959 2/20 0.42
KCNH2 Q12809 1/20 0.42
AR P10275 3/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CYP2A6 P11509 1/20 0.38
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632752 0.86 CNR2 (0.45) ARCYP2A6ALDH1A1HSD17B10KDM4E
SCHEMBL16632567 0.85 CYP2A6 (0.38) SLC6A2SLC6A3ARCA1CA2
SCHEMBL16632984 0.84 CYP2A6 (0.45) ARCA1CA2CYP2A6ALDH1A1
SCHEMBL16632723 0.82 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3KCNH2AR
SCHEMBL5584528 0.76 CYP2A6 (0.50) CA1CA2CYP2A6ALDH1A1KDM4E
SCHEMBL16632621 0.74 AR (0.40) ARPGR
SCHEMBL16632454 0.73 AR (0.41) ARCA1CA2CYP2A6L3MBTL1
SCHEMBL16632419 0.73 AR (0.52) SLC6A4SLC6A2SLC6A3KCNH2AR
SCHEMBL16632622 0.72 CNR2 (0.45) ARCA1CA2CYP2A6ALDH1A1
SCHEMBL806615 0.70 CNR2 (0.45) CYP2A6PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR SLC6A4 4266/4885SLC6A2 3227/4885SLC6A3 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.